The Effect of Gene Mutations on Disease Severity Scores in Pediatric Familial Mediterranean Fever Patients
Öz
Objectives: Familial Mediterranean Fever (FMF) is a self-limiting autoinflammatory disease. In order to better understand the prognosis of diseases, disease severity scores are used. The aim of this study is to determine the effect of genetic mutations on disease severity scores in children with FMF.
Methods: 303 patients between the ages of 0-18, who were diagnosed with FMF according to Yalçınkaya-Özen diagnostic criteria and whose gene analysis was studied, were evaluated retrospectively. Pras et al's scoring system, Mor et al's scoring system and International severity score of FMF (ISSF) scoring system were applied to all patients. Genotypes were compared according to disease severity scores.
Results: When the patients were divided into 4 groups as M694V homozygous, heterozygous, M694V/other allele combined heterozygous and other mutations, according to the score of Pras et al., the frequency of mild disease tended to be less in the M694V homozygous group. When the patients divided as homozygous M694V, heterozygous M694V, heterozygous E148Q, heterozygous M694V/M680I combined mutations, according to the score of Pras et al., mild disease was found to be less common in the homozygous M694V group. When patients were divided into homozygous and heterozygous M694V groups, the disease was more severe in the homozygous M694V group according to the three scoring systems.
Conclusions: Based on the scoring system described by Pras et al., the rate of severe disease was higher in patients with homozygous M694V allele, whereas the rate of mild disease was statistically significantly higher in the heterozygous group compared with homozygous group.
Anahtar Kelimeler
Familial Mediterranean Fever, genotype, disease severity scores, clinic, treatment
Kaynakça
- REFERENCES 1. Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol. 2014; 10(3):135-47.
- 2. Yalçınkaya F, Group TFS. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. 2005.
- 3. Lidar M, Livneh A. Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med. 2007; 65(9): 318-24.
- 4. Cobankara V. Kiraz S. Ailesel akdeniz ateşi Hacettepe Tıp Dergisi Hacettepe Üniversitesi yayınları Ankara. 2000; 31: 310-9.
- 5. Tufan A, Lachmann HJ. Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turk J Med Sci. 2020;50(SI-2): 1591-610.
- 6. Consortium FF. A candidate gene for familial Mediterranean fever. Nature genetics. 1997; 17(1): 25-31.
- 7. Schnappauf O, Chae JJ, Kastner DL, Aksentijevich I. The Pyrin Inflammasome in Health and Disease. Front Immunol. 2019; 10: 1745.
- 8. Pras E, Livneh A, Balow Jr JE, et al. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. American journal of medical genetics. 1998; 75(2): 216-9.
- 9. Mor A, Shinar Y, Zaks N, et al., editors. Evaluation of disease severity in familial Mediterranean fever. Seminars in arthritis and rheumatism; 2005: Elsevier.
- 10. Demirkaya E, Acikel C, Hashkes P, et al. Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Annals of the Rheumatic Diseases. 2016; 75(6): 1051-6.